ESMO – European Society for Medical Oncology posted on LinkedIn:
“Phaeochromocytomas and paragangliomas (PPGLs) and adrenocortical carcinoma (ACC) are Rare Cancers with heterogeneous outcomes, but only limited information is available on prognostic factors.
As presented at ESMO Rare Cancers25, ctDNA tumour fraction was detectable in 19% of metastatic PPGL and was associated with 24-month overall survival (OS) rates of 24% versus 85% when ctDNA was undetected.
In a second study, researchers developed a new scoring system for ACC based on tumour burden, cortisol levels, performance status and neutrophil-to-lymphocyte ratio, with high scores associated with shorter OS.
Commentary from Alfredo Berruti in the ESMO Daily Reporter.”
Read Further about ESMO Rare Cancers 2025.